Avere Therapeutics

Avere Therapeutics is a biotechnology company focused on oral therapies for IL-23-driven inflammatory diseases. Its lead and currently disclosed program is AVR-001, a differentiated oral peptide interleukin-23 receptor antagonist being developed as a once-weekly therapy. The company emerged publicly in July 2026 through a definitive reverse-merger agreement with NextCure, alongside a $320 million private financing. Avere is initially prioritizing psoriasis and ulcerative colitis, with Phase 1b psoriasis data already generated and further mid-stage and late-stage development planned. The management team is led by former Akero Therapeutics executives, positioning the company as an immunology-focused clinical-stage biotech.